Nakayama, Robert <br/><br/>
Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma.  [electronic resource] 

 -  Oncotarget  Mar 2016 
 - 16581-92 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.7667  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Apoptosis--drug effects<br/>Blotting, Western<br/>Cell Line, Tumor<br/>Cell Survival--drug effects<br/>Dose-Response Relationship, Drug<br/>Drug Screening Assays, Antitumor--methods<br/>Female<br/>G1 Phase Cell Cycle Checkpoints--drug effects<br/>Humans<br/>Hydrazines--pharmacology<br/>Karyopherins--antagonists & inhibitors<br/>Mice, Nude<br/>Proto-Oncogene Proteins c-kit--genetics<br/>Receptors, Cytoplasmic and Nuclear--antagonists & inhibitors<br/>Reverse Transcriptase Polymerase Chain Reaction<br/>Sarcoma--drug therapy<br/>Signal Transduction--drug effects<br/>Triazoles--pharmacology<br/>Xenograft Model Antitumor Assays--methods<br/>Exportin 1 Protein